Cancer Committee passes Korean-made new drug Leclaza
By Eo, Yun-Ho | translator Byun Kyung A
21.02.24 15:36:55
가나다라
0
HIRA Cancer Deliberation Committee approves of NHI coverage a month after Leclaza was authorized
DREC and NHIS pricing negotiation also expected to be processed swiftly
A pharmaceutical industry source reported the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee has approved of the NHI reimbursement on Yuhan Corporation’s Leclaza (lazertinib), a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) like Tagrisso (osimertinib), on Feb. 24.
With the current swift processing, the Drug Reimbursement Evaluation Committee (DREC) and the National Health Insurance Service (NHIS) pricing negotiation procedure would also be processed quickly. Leclaza is highly likely to be liste
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)